Clinic dosing of beta blockers in chronic heart failure

T M Ramahi1, R Rohlfs, N Sheynberg

  • 1Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510.

Insights

Initiating beta-blocker therapy for chronic heart failure patients does not require a 1-hour observation period. Stable patients can safely start and adjust beta-blocker doses at home, reducing healthcare costs.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta blockers are crucial for improving survival and reducing morbidity in chronic heart failure (CHF).
  • Current guidelines mandate a 1-hour observation post-initiation or up-titration of beta-blocker therapy.
  • This observation period may increase healthcare costs and limit beta-blocker utilization.

Purpose of the Study:

  • To evaluate the necessity and safety of the 1-hour in-clinic observation period for beta-blocker therapy in CHF patients.
  • To determine if beta-blockers can be safely initiated and up-titrated at home for stable CHF patients.

Main Methods:

  • Retrospective analysis of 130 in-clinic observation periods for 34 stable CHF patients on carvedilol.
  • Patients had severe left ventricular dysfunction (mean ejection fraction 0.22±0.09) and were in functional class 2.5±0.6.
  • Blood pressure and heart rate were monitored hourly during 1-2 hour observation periods post-initiation or dose increase.

Main Results:

  • No patients required a dose reduction during the in-clinic observation periods.
  • A slight but statistically significant decrease in blood pressure was observed 1 hour post-dosing (p < 0.001).
  • Adverse events requiring dose decrease or discontinuation occurred days after dosage increases, not during clinic observation.

Conclusions:

  • The 1-hour in-clinic observation period for beta-blocker initiation/up-titration in stable CHF patients is not essential.
  • Properly selected and evaluated stable CHF patients can safely initiate and up-titrate beta-blockers at home.
  • Home-based titration can potentially reduce healthcare expenses and improve access to beta-blocker therapy.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.